RATIONALE: The dopamine (DA) D2 and D3 receptors have been associated with cocaine abuse. A recent study with the D3 receptor (D3R) partial agonist PG619 found that it attenuated cocaine-induced reinstatement and the D2-like receptor antagonist buspirone has shown positive outcomes in two studies of cocaine abuse in monkeys. However, a recent clinical trial indicated that buspirone did not improve abstinence in treatment-seeking cocaine abusers. OBJECTIVE: The objective of the study was to examine PG619 and buspirone under a food-drug choice paradigm in order to better model the clinical findings. In addition, we extended the characterization of both compounds to include methamphetamine (MA) self-administration (SA). METHODS: Six adult male rhesus monkeys were trained to respond under a concurrent food (1.0-g pellets) and drug (0.01-0.3 mg/kg/injection cocaine or MA) choice paradigm in which complete SA dose-response curves were determined each session (N = 3/group). Monkeys received 5 days of treatment with either PG619 (0.1-3.0 mg/kg, i.v.) or buspirone (0.01-1.0 mg/kg, i.m.). In a follow-up study, the SA doses were reduced (0.003-0.1 mg/kg/injection) to increase reinforcement frequency and buspirone was retested. RESULTS: PG619 did not affect cocaine or MA choice, while buspirone increased low-dose cocaine choice. Changing the SA doses increased the number of reinforcers received each session, but buspirone did not decrease drug choice. CONCLUSIONS: Consistent with clinical findings, these results do not support the use of buspirone for psychostimulant abuse and suggest that food-drug choice paradigms may have greater predictive validity than the use of other schedules of reinforcement.
RATIONALE: The dopamine (DA) D2 and D3 receptors have been associated with cocaine abuse. A recent study with the D3 receptor (D3R) partial agonist PG619 found that it attenuated cocaine-induced reinstatement and the D2-like receptor antagonist buspirone has shown positive outcomes in two studies of cocaine abuse in monkeys. However, a recent clinical trial indicated that buspirone did not improve abstinence in treatment-seeking cocaine abusers. OBJECTIVE: The objective of the study was to examine PG619 and buspirone under a food-drug choice paradigm in order to better model the clinical findings. In addition, we extended the characterization of both compounds to include methamphetamine (MA) self-administration (SA). METHODS: Six adult male rhesus monkeys were trained to respond under a concurrent food (1.0-g pellets) and drug (0.01-0.3 mg/kg/injection cocaine or MA) choice paradigm in which complete SA dose-response curves were determined each session (N = 3/group). Monkeys received 5 days of treatment with either PG619 (0.1-3.0 mg/kg, i.v.) or buspirone (0.01-1.0 mg/kg, i.m.). In a follow-up study, the SA doses were reduced (0.003-0.1 mg/kg/injection) to increase reinforcement frequency and buspirone was retested. RESULTS:PG619 did not affect cocaine or MA choice, while buspirone increased low-dose cocaine choice. Changing the SA doses increased the number of reinforcers received each session, but buspirone did not decrease drug choice. CONCLUSIONS: Consistent with clinical findings, these results do not support the use of buspirone for psychostimulant abuse and suggest that food-drug choice paradigms may have greater predictive validity than the use of other schedules of reinforcement.
Authors: Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish Journal: J Neurosci Date: 2012-01-25 Impact factor: 6.167
Authors: Jennifer L Martelle; Renee Claytor; Jason T Ross; Beth A Reboussin; Amy Hauck Newman; Michael A Nader Journal: J Pharmacol Exp Ther Date: 2007-02-01 Impact factor: 4.030
Authors: Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2013-08-07 Impact factor: 7.853
Authors: Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick Journal: Int J Neuropsychopharmacol Date: 2012-07-25 Impact factor: 5.176
Authors: Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang Journal: Int J Neuropsychopharmacol Date: 2006-02-01 Impact factor: 5.176
Authors: Theresa M Winhusen; Frankie Kropp; Robert Lindblad; Antoine Douaihy; Louise Haynes; Candace Hodgkins; Karen Chartier; Kyle M Kampman; Gaurav Sharma; Daniel F Lewis; Paul VanVeldhuisen; Jeff Theobald; Jeanine May; Gregory S Brigham Journal: J Clin Psychiatry Date: 2014-07 Impact factor: 4.384
Authors: William S John; Thomas J Martin; Kiran Kumar Solingapuram Sai; Susan H Nader; H Donald Gage; Akiva Mintz; Michael A Nader Journal: J Pharmacol Exp Ther Date: 2017-12-04 Impact factor: 4.030
Authors: Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs Journal: Behav Pharmacol Date: 2018-02 Impact factor: 2.293